Article Text
Editorial
Dual antiplatelet therapy in the ‘real world’
Statistics from Altmetric.com
Footnotes
Contributors ENCO drafted the article which was critically revised by RFS and WAEP.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests RFS: institutional research grants/support from AstraZeneca and PlaqueTec; consultancy fees from AstraZeneca, Actelion, Avacta, Bayer, Bristol Myers Squibb/Pfizer, Idorsia, Novartis, PlaqueTec, and The Medicines Company; speaker fees from AstraZeneca and Bayer.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.